Relapsing vivax malaria after 6 months of daily atovaquone/proguanil in Afghanistan: the case for expanded use of primaquine as a causal prophylactic.
A 22-year-old soldier presented with vivax malaria after extended travel in Afghanistan. Compliant with atovaquone/proguanil in country, he discontinued prophylaxis immediately upon departure. This case raises important issues regarding prophylactic choice and compliance during travel to Plasmodium vivax endemic locations and primaquine's registration status for prophylaxis and use by practitioners.
Maguire
Jason D
JD
U.S. Military Hospital, Expeditionary Medical Facility, Arifjan, Kuwait. jason.maguire@med.navy.mil
Llewellyn
David M
DM
D000328:Adult; D000346:Afghanistan; D000962:Antimalarials / Q000008:administration & dosage*; D053626:Atovaquone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D016780:Malaria, Vivax / Q000517:prevention & control*; D008297:Male; D015767:Mefloquine / Q000008:administration & dosage; D008889:Military Personnel; D010349:Patient Compliance; D011319:Primaquine / Q000008:administration & dosage; D002727:Proguanil / Q000008:administration & dosage; D012008:Recurrence; D014195:Travel
D000962:Antimalarials; D011319:Primaquine; D002727:Proguanil; D015767:Mefloquine; D053626:Atovaquone